Skip to main content

COO

Stock
Health Care
Medical Instruments & Supplies

Performance overview

COO Price
Price Chart

Forward-looking statistics

Beta
0.38
Risk
25.86%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.

Company info

SectorHealth Care
IndustryMedical Instruments & Supplies
Employees8K
Market cap$18.8B

Fundamentals

Enterprise value$16.9B
Revenue$4.0B
Revenue per employee—
Profit margin10.39%
Debt to equity34.50

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$2.07
Dividend per share$0.06
Revenue per share$19.99
Avg trading volume (30 day)$237M
Avg trading volume (10 day)$237M
Put-call ratio—

Macro factor sensitivity

Growth-0.9
Credit+3.5
Liquidity+0.3
Inflation-3.0
Commodities-0.3
Interest Rates-2.3

Valuation

Dividend yield0.08%
PEG Ratio17.97
Price to sales3.67
P/E Ratio17.97
Enterprise Value to Revenue4.25
Price to book1.76

Upcoming events

Next earnings dayAugust 27, 2025
Next dividend day—
Ex. dividend dayJuly 26, 2023

News

COO Stock Declines Despite Strong Core Growth Amid Fertility Woes

The Cooper Companies grows margins and premium products, but fertility softness, inventory cuts, and tariffs weigh on the near-term outlook.

Zacks Investment Research (July 2, 2025)
HOLX vs. COO: Which GYN Surgical Stock Is the Better Investment Now?

As demand for GYN surgical tools climbs, HOLX and COO battle it out. Find out which stock shows stronger growth momentum now.

Zacks Investment Research (June 23, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free